On February 18, Chinese pharmaceutical enterprise Zhuhai Beihai Biotechnology Co., LTD. ("Beihai Biotechnology") announced that it has entered into a major strategic partnership with Zydus Lifesciences, an Indian pharmaceutical company, granting exclusive commercialization rights to its new drug BEIZRAY (Docetaxel-BH009) in the US market. The news pointed out that BEIZRA is the first docetaxel improved new drug that has passed clinical validation and has obvious clinical advantages nearly three decades after the launch of docetaxel. It is also the first modified new drug in recent years to successfully achieve a licensing deal for export from China to the United States.
Under the terms of the agreement, BEIZRAY will be manufactured and supplied by Beizray, and Zydus Pharmaceuticals, Zydus' U.S. subsidiary, will commercialize the product in the United States. The company will receive an initial payment of USD 15 million (CNY 109 million, to be paid upon signing of the agreement) and USD 10 million (CNY 73 million, to be paid upon initial product delivery) as well as a number of sales milestones and a high double-digit profit share.
According to IQVIA MAT's data in December 2024, the annual dosage of docetaxel injection in the U.S. market is about 531,000 doses. As a cornerstone cancer treatment drug, docetaxel has had annual global sales of more than USD 2 billion (CNY 15 billion) since its launch in 1996.
Biobai is an innovative biomedical enterprise, with molecular targeted delivery technology platform and PDC coupled drug technology platform, has laid out more than 10 differentiated innovative drug research and development pipelines, a number of new drug projects have entered the clinical stage, and has obtained 11 new drug clinical trial licenses (IND) in China and the United States.